Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have announced a strategic partnership to develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. This collaboration aims to leverage Teva's innovative drug development expertise and Fosun Pharma's strong oncology development experience, particularly in the China market. Under the agreement, Fosun Pharma receives an exclusive license to develop, manufacture, and commercialize the therapy in various Asian regions, while Teva retains rights for the rest of the world. The partnership is expected to accelerate clinical data generation and advance the global development of this promising cancer treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.